Last reviewed · How we verify
three consecutive lots of EV71 vaccine
three consecutive lots of EV71 vaccine is a Inactivated viral vaccine Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently in Phase 3 development for Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71, Prevention of EV71-associated neurological complications in pediatric populations. Also known as: Vaccine groups.
An inactivated enterovirus 71 (EV71) vaccine that stimulates the immune system to produce antibodies against EV71, preventing infection and disease.
An inactivated enterovirus 71 (EV71) vaccine that stimulates the immune system to produce antibodies against EV71, preventing infection and disease. Used for Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71, Prevention of EV71-associated neurological complications in pediatric populations.
At a glance
| Generic name | three consecutive lots of EV71 vaccine |
|---|---|
| Also known as | Vaccine groups |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated viral vaccine |
| Target | Enterovirus 71 (EV71) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated EV71 virus particles that trigger both humoral (antibody) and cellular immune responses. This immunization protects against hand, foot, and mouth disease (HFMD) and other EV71-associated complications by enabling the body to recognize and neutralize the virus upon exposure.
Approved indications
- Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71
- Prevention of EV71-associated neurological complications in pediatric populations
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Irritability or fussiness
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- three consecutive lots of EV71 vaccine CI brief — competitive landscape report
- three consecutive lots of EV71 vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about three consecutive lots of EV71 vaccine
What is three consecutive lots of EV71 vaccine?
How does three consecutive lots of EV71 vaccine work?
What is three consecutive lots of EV71 vaccine used for?
Who makes three consecutive lots of EV71 vaccine?
Is three consecutive lots of EV71 vaccine also known as anything else?
What drug class is three consecutive lots of EV71 vaccine in?
What development phase is three consecutive lots of EV71 vaccine in?
What are the side effects of three consecutive lots of EV71 vaccine?
What does three consecutive lots of EV71 vaccine target?
Related
- Drug class: All Inactivated viral vaccine drugs
- Target: All drugs targeting Enterovirus 71 (EV71)
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71
- Indication: Drugs for Prevention of EV71-associated neurological complications in pediatric populations
- Also known as: Vaccine groups
- Compare: three consecutive lots of EV71 vaccine vs similar drugs
- Pricing: three consecutive lots of EV71 vaccine cost, discount & access